DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Diametica Therapeutics second quarter 2026 earnings conference call. An audio recording of this webcast will be available shortly after the call today on Diametica's website at www.diametica.com in the investor relations section. Before the company proceeds with its remarks, Please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results, appear in the section entitled Cautionary Statements Note regarding forward-looking statements in the company's press release issued yesterday and under the heading Risk Factors in Diametica's most recent annual report on Form 10-K and most recent quarterly report on Form 10-Q. Diametica's SEC filings are available at www.sec.gov and on its website. Diomedica's President and Chief Executive Officer, Mr. Pauls. You may begin. Thank you, Morgan, and thank you all for joining us today. With me this morning are Dr. Julie Krop, our Chief Medical Officer, and Scott Kellen, our Chief Financial Officer. Q2 was an important quarter for Diomedica, with progress across DL-19 in early-onset fetal growth restriction, preeclampsia, and acute ischemic stroke. We advanced our pregnancy-related clinical strategy, continued preparations for our Phase II early-onset preeclampsia study in Canada and the UK, and made further progress towards reaching the planned Phase 2-3 Remedy 2 Interim Analysis in Acute Ischemic Stroke. There are four key updates I would like to highlight. First, with respect to the IST being conducted by Pro...